Theralase's (CVE:TLT) cold laser tech can be cancer game changer believes CEO: ProactiveInvestors Stocktube

ProactiveInvestors Stocktube

Published on Sep 2, 2016

Theralase Technologies Inc’s (CVE:TLT) therapeutic laser division is growing strongly but using cold lasers to treat cancer is the potential game changer says chief executive Roger Dumoulin-White.

Theralase’s therapeutic lasers are used to treat pain. 

Sales this year are set to jump to US$5mln, from US$2mln, after the US approved an upgraded version last year.

These revenues are helping to fund the anti-cancer business that is targeting non-muscle invasive bladder cancer.

A phase 1b trial is next and Dumoulin-White believes that, once proven, its technology could take a 25% share of the US$4bn market in the US in as little as three years.

http://www.4-traders.com/THERALASE-TECHNOLOGIES-IN-1411951/
http://www.4-traders.com/THERALASE-TECHNOLOGIES-IN-15578670/